Publisher
Springer Berlin Heidelberg
Reference67 articles.
1. Koyama Y(1983) Pharmacokinetics and clinical trials of HuIFN-b in malignant tumors. In: KishidaT (ed) Interferons. Kyoto, pp 185–195
2. Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM (1986) Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med 80:223–228.
3. Steis RG, Smith JWd, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL (1988) Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318:1409–1413.
4. Balemans LT, Mattijssen V, Steerenberg PA, Van Driel BE, De Mulder PH, Den Otter W (1993) Locoregional therapy with polyethylene-glycol-modified interleukin-2 ot an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity. Cancer Immunol Immunother 37:7–14.
5. Nathanson L (1972) Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG. Cancer Chemother Rep 56:659–665.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Onkologische Dermatologie;Fallstricke und Fehlerquellen in der Dermatologie;2004
2. Therapeutischer Einsatz von Interleukin-2 beim Melanom;Dermatologie an der Schwelle zum neuen Jahrtausend;2000